Oncoinvent ASA (STU:7BG) Research & Development: €6.75 Mil (TTM As of Dec. 2025)


STU:7BG Oncoinvent ASA STU:7BG
36 GF Score
Price €4.32
GF Value €84.74
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Research & Development?

Oncoinvent ASA STU:7BG -22.86% 36 Research & Development is €6.75 Mil as of Dec. 2025. GuruFocus rates STU:7BG with a GF Score™ of 36/100 and a GF Value™ of €84.74. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Oncoinvent ASA's Research & Development for the six months ended in Dec. 2025 was €3.84 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €6.75 Mil.

Oncoinvent ASA  (STU:7BG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Oncoinvent ASA Research & Development Related Terms

Oncoinvent ASA Research & Development Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA Research & Development Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.28 19.34 9.37 4.43 5.31

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.40 4.72 1.64 2.91 3.84
STU:7BG
36GF Score
Oncoinvent ASA STU:7BG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €6.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €6.75 Mil mean?
Oncoinvent ASA (STU:7BG) has a Research & Development of €6.75 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Research & Development too high?
Oncoinvent ASA's current Research & Development is €6.75 Mil. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Research & Development compare to VRTX and REGN?
Oncoinvent ASA's Research & Development of €6.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Research & Development is €6.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (STU:7BG) has a current Research & Development of €6.75 Mil. The stock's GF Value™ is €84.74, compared to a current price of €4.32 — trading 94.9% below its estimated fair value. The current Research & Development is €6.75 Mil. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Oncoinvent ASA (STU:7BG), the current Research & Development is €6.75 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (STU:7BG) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of €4.32 is trading 94.9% below its estimated GF Value™ of €84.74.

Key valuation signals for STU:7BG:

  • Research & Development: €6.75 Mil
  • GF Value™: €84.74 vs. price of €4.32 (94.9% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the STU:7BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for STU:7BG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.32
Price
€84.74
GF Value